High Dose Oxytocin Nasal Spray for Treatment of Tinnitus
NCT04210310 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 33
Last updated 2022-10-05
Summary
The purpose of this study is to evaluate the effects of high-dose intranasal oxytocin for treating tinnitus. The hypothesis is that high dose intranasal oxytocin can significantly reduce tinnitus severity and disability.
Conditions
- Tinnitus
Interventions
- DRUG
-
Oxytocin
The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day
- OTHER
-
Placebo nasal spray
A placebo nasal spray, consisting of magnesium, chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both active drug and the placebo will appear identical in the glass bottles. The placebo will be administered in the same manner as the active study drug, with 1 puff in one nostril four times per day.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Lawrence Newman, MD · NYU Langone
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-01-15
- Primary Completion
- 2022-05-10
- Completion
- 2022-05-10
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
OTO-313 in Subjects With Subjective Tinnitus
NCT03918109 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus
NCT00860808 ·Status: COMPLETED ·Phase: PHASE2
-
AM-101 in the Treatment of Acute Tinnitus 3
NCT02040194 ·Status: COMPLETED ·Phase: PHASE3
-
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
NCT04129775 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus
NCT03336398 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus
NCT01270282 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss
NCT02414152 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Protective Effects of EPI-743 on Noise-Induced Hearing Loss
NCT02257983 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial
NCT05650645 ·Status: COMPLETED ·Phase: PHASE2
-
Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift
NCT01444846 ·Status: COMPLETED ·Phase: PHASE2
-
Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity
NCT01108601 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
AM-101 in the Treatment of Post-Acute Tinnitus 1
NCT01934010 ·Status: COMPLETED ·Phase: PHASE3
-
Prevention of Noise-induced Hearing Loss
NCT02049073 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss
NCT05664100 ·Status: TERMINATED ·Phase: PHASE1
-
Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays
NCT00279916 ·Status: COMPLETED ·Phase: PHASE3
-
High Dose Oral Steroids in Sudden Sensorineural Hearing Loss
NCT03255473 ·Status: WITHDRAWN ·Phase: PHASE2
-
Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
NCT06025097 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
TNF-α Treatment of Blast-Induced Tinnitus
NCT04066348 ·Status: RECRUITING ·Phase: PHASE2
-
Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss
NCT02038972 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Verification of the Efficacy/safety of the Intratympanic Drug Delivery for Hearing Loss
NCT04766853 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Sudden Hearing Loss Multi-center Clinical Trial
NCT02026479 ·Status: UNKNOWN ·Phase: NA
-
Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
NCT02997189 ·Status: TERMINATED ·Phase: PHASE2
-
Safety Study for NST-001 and the Neuroject Injection Set to Treat Tinnitus
NCT00957788 ·Status: TERMINATED ·Phase: PHASE1
-
Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)
NCT04774250 ·Status: TERMINATED ·Phase: PHASE2
-
Performance and Safety of Otinova® Ear Spray
NCT05370209 ·Status: TERMINATED ·Phase: NA